Terms ending in 2034
Every in-force patent on Irm LLC's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,649,359 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Irm LLC | In force | High confidence | |
| US 10,239,927 | Peptides and Compositions for Treatment of Joint Damage In force · Low confidence | Novartis AG | In force | Low confidence | |
| US 10,328,126 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | |
| US 10,533,042 | Peptides and Compositions for Treatment of Joint Damage In force · Low confidence | Novartis AG | In force | Low confidence | |
| US 11,179,442 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,789,203 | Antibody Drug Conjugates In force · High confidence | Novartis AG | In force | High confidence | |
| US 10,786,578 | Ckit Antibody Drug Conjugates In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,301,971 | Peptides and Compositions for Treatment of Joint Damage In force · High confidence | Irm LLC. | In force | High confidence | |
| US 11,111,283 | Peptides and Compositions for Treatment of Joint Damage In force · Low confidence | Novartis AG | In force | Low confidence | |
| US 11,370,820 | Peptides and Compositions for Treatment of Joint Damage In force · Medium confidence | Novartis AG | In force | Medium confidence | |
| 11 more term ends in 2034 · Pro | |||||
10 of 21 patents shown. Soonest term end first, then patent number.
Pro members see all 21.
3 of these are in force and held by Irm LLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.